Jan 10 (Reuters) - INTERVACC AB:
* SIGNIFICANT PROGRESS HAS BEEN MADE IN THE DEVELOPMENT OF A NEW VACCINE AGAINST STAPHYLOCOCCUS AUREUS INFECTIONS
* ‍COSTS RELATED TO MASTITIS ARE ESTIMATED ANNUALLY ABOUT 200 MSEK ONLY IN SWEDEN AND IN US ABOUT 4500 MSEK​
* SAYS ‍NEED FOR A VACCINE TO COMPLEMENT OTHER PREVENTIVE MEASURES IS VERY LARGE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.